Paliperidone Palmitate 525 mg eq.
Sponsors
Janssen Research & Development, LLC, Janssen-Cilag International NV
Conditions
Schizophrenia
Phase 4
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
CompletedNCT03713658
Start: 2018-10-18End: 2019-12-02Updated: 2025-04-27
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
CompletedNCT04940039
Start: 2021-07-22End: 2024-04-16Updated: 2025-04-27